Our Publications

OUR PUBLICATIONS

Our Publications

About DAV132

ArticlesPosters
CLINICAL DATA Pinquier JL et al. A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects. Clin Pharmacol in Drug Dev (2021). LinkCLINICAL DATA Ducher A et al. DAV132 protects intestinal microbiota of patients treated with quinolones. A European phase II randomized controlled trial. IDWeek 2020, Oral presentation.
CLINICAL DATA Guk J et al. Modeling the Effect of DAV132, a Novel Colon-Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers. Clin Pharmacol Ther (2020). LinkCLINICAL DATA Ducher A et al. DAV132 protects intestinal microbiota of patients treated with quinolones. A European phase II randomized controlled trial. ECCMID 2020, Abstract 9918. Link
Chilton CH et al. Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model. J Antimicrob Chemother (2020). LinkCLINICAL DATA Ducher A et al. Dose-effect and safety of DAV132, an activated charcoal based product, when given with oral moxifloxacin on free moxifloxacin fecal concentrations and intestinal microbiota diversity: a randomized controlled trial in 144 healthy volunteers. ECCMID 2018, poster 0758. Link
Burdet C et al. Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. Antimicrob Agents Chemother (2019). LinkBurdet C et al. Change in bacterial diversity of fecal microbiota drives mortality in a hamster model of antibiotic-induced Clostridium difficile colitis. IDWEEK 2017, poster 1251. Link
Saint-Lu N et al. DAV131A protects hamsters from lethal Clostridioides difficile infection induced by fluoroquinolones. Antimicrob Agents Chemother (2019). LinkSaint-Lu N et al. Extended protection by DAV131A against antibiotic-induced Clostridium difficile infection in hamsters. ASM Microbes 2016. Link
CLINICAL DATA De Gunzburg et al. Protection of the Human Gut Microbiome From Antibiotics. The Journal of Infectious Diseases (2018). LinkCLINICAL DATA de Gunzburg et al., DAV132, an Adsorbent-Based Product, Protects the Gut Microbiome and Prevents Clostridium difficile Infections during Moxifloxacin Treatments. IDWEEK 2015, poster 129_760. Link
Burdet C et al. Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection. Antimicrob Agents Chemother (2018). LinkCLINICAL DATA Ducher A et al. DAV132, developed to prevent side effects of antibiotics in the gut flora: Results of a pilot cross-over study in healthy volunteers. ECCMID 2014, poster P0248. Link
Burdet C et al. Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis. Antimicrob Agents Chemother (2017). LinkMiossec C et al. DAV131, an oral adsorbent-based product, exerts a dose-dependent protection of hamsters against moxifloxacin-induced Clostridium difficile lethal infection. ECCMID 2014, poster P0804. Link
CLINICAL DATA De Gunzburg et al. Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: A proof of concept study in healthy subjects. The Journal of Clinical Pharmacology (2014). LinkGrall N et al. Can DAV132, a Medical Device Releasing an Adsorbent into the Late Ileum, Decrease Significantly the Impact of Antibiotics on the Fecal Microbiota? ICPIC 2013, Geneva. Link
Grall N et al. Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice. Antimicrob Agents Chemother (2013). LinkMiossec C et al. DAV131, an Oral Adsorbent-based Product Fully Protects Hasmters Against Moxifloxacin induced Clostridium difficile Lethal Infection. ICAAC 2013, poster F-631a. Link
Sayah-Jeanne S et al. Decrease of Levofloxacin Fecal Concentrations in Experimental Dogs Using DAV132, an Oral Adsorbent Delivered to the Ileum/Colon .ICAAC 2012. Link

About C. difficile infection

ArticlesPosters
Harris HC et al. Optimisation of an assay to determine colonisation resistance to Clostridioides difficile in faecal samples from healthy subjects and those treated with antibiotics. Antimicrob Agents Chemother (2020). LinkLurienne L et al. Incidence of CDI in a cohort of US patients with newly diagnosed Acute Myeloid Leukemia receiving intensive chemotherapy. ASH 2020, poster 3406. Link
Duhalde L et al. The economic burden of Clostridioides difficile infection in patients with hematological malignancies in the United States: A case-control study. Infect Control Hosp Epidemiol (2020). LinkDuhalde L et al. The economic burden of Clostridioides difficile infection in patients with haematological malignancies: a case-control study. ECCMID 2020, Abstract 395.Link
Lurienne L et al. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. Journal of Patient-Reported Outcomes (2020). LinkHeimann SM et al. Healthcare resource utilisation for treatment of Clostridioides difficile infection across 12 European countries: health economic results of COMBACTE-CDI. ECCMID 2020, Abstract 3529. Link
Duhalde L et al. Excess burden associated with Clostridioides difficile infection in haematological patients occurring during hospitalization with induction chemotherapy in the United States. Journal of Hospital Infection (2019). LinkBerkell M et al. Increased enterococcal abundance and low microbial diversity are early predictive markers of a microbiota primed for development of Clostridioides difficile infection. ECCMID 2020, Abstract 9817. Link
Mollard S et al. Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016. Journal of Hospital Infection (2019). LinkLurienne L et al. Perception of Quality of Life Among People Experiencing or Having Experienced a Clostridium difficile Infection in the United States: Qualitative Review of Respondents Verbatim. ACG 2018, poster P1877. Link
Leblanc S et al. Burden of Clostridium difficile Infection in French Hospital in 2014 From the National Health Insurance Perspective. Infection Control & Hospital Epidemiology (2017). LinkVan Werkhoven CH et al. Incidence of antibiotic-associated diarrhea and Clostridium difficile infection in Europe. ECCMID 2018. Link
Leblanc S et al. Burden of Clostridium difficile Infection in French Hospital in 2014 From the National Health Insurance Perspective. RICAI 2016. Link

About Immuno-Oncology

ArticlesPosters
Lurienne L et al. Non-small-cell lung cancer immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol (2020). Link
Zalcman G et al. Update of Systematic Reviews and Meta-Analyses Studying the Association Between Antibiotic Use and Clinical Outcomes of Cancer Patients Treated with Immune Checkpoint Inhibitors. ESMO Immuno-Oncology Virtual Congress 2020. Link
Crespin et al. Update of a Systematic Review and Meta Analysis Studying the Association Between Antibiotic Use and Clinical Outcomes of Non Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. SITC Virtual Congress 2020. Link
Cervesi J et al. A Review of Meta-Analyses on the Impact of Antibiotics on the Efficacy of Immune Checkpoint Inhibitors and Cancer Patients’ Survival. ESMO Virtual Congress 2020. Link

About Microbiome Disruption & Resistance to Antibiotics

ArticlesPosters
Andremont A et al. Spare and repair the gut microbiota from antibiotic-induced dysbiosis: state-of-the-art . Drug Discovery Today. (2021). Link
Dupouy VM et al. Prevalence of beta-lactam and quinolone/fluoroquinolone resistance in Enterobacteriaceae from dogs in France and Spain - Characterization of ESBL/pAmpC isolates, genes and conjugative plasmids. Front. Vet. Sci. (2019). Link
Nguyen TT et al. Correlation between Fecal Concentrations of Ciprofloxacin and Fecal Counts of Resistant Enterobacteriaceae in Piglets Treated with Ciprofloxacin: toward New Means To Control the Spread of Resistance?. Antimicrob Agents Chemother (2011). Link